TPD52L2 and nonpapillary renal cell carcinoma: Despite the comprehensive analysis and in vitro experiments conducted in this study, which revealed TPD52L2 as an unfavorable prognostic biomarker for ccRCC and its promotion of malignant biological behavior in ccRCC cells, its practical application in clinical remains a challenge.